Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients

The aging-related premalignant condition known as clonal hematopoiesis of indeterminate potential (CHIP) is characterized by a distinct subset of hematopoietic stem cells (HSCs) carrying one or more somatic mutations, typically in myeloid malignancy–associated genes. This subset of HSCs produces a clonal population of blood cells that can be identified in blood samples from individuals before symptoms are ever present (in ~10% of people over 65 years old). Even with CHIP, most of these individuals are at low risk of acquiring a hematologic malignancy.

In their recent Experimental Hematology paper, Zhang and colleagues investigated the role of environmental factors, specifically inflammation, on the mutational spectrum of CHIP blood cell subpopulations [1]. They postulated that in addition to compromising HSC function, an inflammatory environment may also exert selective pressure on HSC mutations associated with CHIP. In their study, they sequenced 40 CHIP-associated genes in the peripheral blood mononuclear cell DNA from 187 patients >50 years old with ulcerative colitis (UC). UC is an inflammatory bowel disease that leads to T cell infiltration of the colon, as well as the overproduction of two pro-inflammatory cytokines, tumor necrosis factor α (TNFα) and interferon γ (IFNγ). They found that the most frequently mutated gene in those UC patients with CHIP was DNMT3A, followed by PPM1D, suggesting that inflammation associated with UC may exert selective pressure on the CHIP mutational spectrum.

In addition to analyzing DNA sequences, Zhang and coauthors quantified patient TNFα and IFNγ levels using the corresponding Invitrogen ProQuantum Immunoassay Kit, which provides a sensitive qPCR-based immunoassay that can detect as little as 0.01 pg/mL cytokine in serum using small sample volumes. The pro-inflammatory cytokine data from the UC patients were matched for patient age and sex, and further grouped into three categories: CHIP (n = 21), CHIP-hs+ (CHIP-high sensitivity with variant allele fraction >0.5%) without DNMT3A mutations (CH+DNMT3A, n = 17), and CHIP-hs+ with DNMT3A mutations (CH+DNMT3A+, n = 19). Whereas serum TNFα levels were not significantly different among patient groups, the CHIP-hs+ CH+DNMT3A+ patients exhibited significantly higher serum IFNγ levels (Figure 1).

In summary, this study showed that ulcerative colitis patients were slightly more likely to have CHIP, and that inflammation associated with ulcerative colitis may be selecting for HSC clones with specific mutations. Further research is needed to explore the relationship between IFNγ levels and DNMT3A mutations.

2 graphs showing cytokine levels per patient as measured with ProQuantum immunoassays

Figure 1. Clonal hematopoiesis of indeterminate potential (CHIP) dynamics in ulcerative colitis (UC) patients. TNFα and IFNγ levels in serum of UC samples in patients surveyed in this experiment, measured using Invitrogen ProQuantum Immunoassay Kits. Each dot indicates the level of a given cytokine in the serum of one patient. Graphs represent means ± SEM. * p < 0.05, one-way ANOVA with Bonferroni multiple test correction. Reprinted from Zhang CRC, Nix D, Gregory M et al. (2019) Exp Hematol 80:36–41 , with permission from Elsevier.

Article download

Download a printer-friendly version of this article.
 Download now

仅供科研使用,不可用于诊断目的。